PAVmed Inc. (PAVM)
$2.69-3.58%Close
SELLCRISIS · day 25
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1M
- Beta
- 0.54
- P/E (TTM)
- -0.16
- Short % float
- 2.86%
- Days to cover
- 1.0
- SI change
- +16.7%
- 1W
- +1.13%
- 1M
- -35.65%
- vs SPY 1W
- +0.71%
- vs SPY 1M
- -37.71%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 4
- GROWTH
- 0
- GARP
- 2
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-20.1%
REV YoY-
ROE-33.5%
EPS YoY-
ROA-30.1%
GROSS-254
OP-23843
NET-10795
[VALUATION]
P/E TTM-0.16
P/E FWD-
SECTOR PE20.34
INDUSTRY PE22.66
P/B0.48
P/FCF-
EV/EBITDA-1.86
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E48.70
ALTMAN Z-
CURR RATIO1.19
ND/EBITDA-
BETA0.54
Company news
FAQ
- What is LOPJLB’s current signal on PAVM?
- LOPJLB’s latest quantitative signal on PAVmed Inc. (PAVM) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is PAVM in?
- PAVmed Inc. (PAVM) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does PAVmed Inc. (PAVM) do?
- PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-gen…